NICE TAs

07/05/2026

TA1152: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

07/05/2026

TA1154: Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)

07/05/2026

TA1153: Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment

06/05/2026

TA1151: Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)

30/04/2026

TA1149: Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma

29/04/2026

TA1148: Sodium zirconium cyclosilicate for treating hyperkalaemia (review of TA599)

29/04/2026

TA1147: vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

28/04/2026

TA1146: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881)

21/04/2026

TA1145: Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma

08/04/2026

TA1144: Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)

31/03/2026

TA1143: Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause

26/03/2026

TA1142: Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

17/03/2026

TA1141: Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)

17/03/2026

TA1140: Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (review of TA1088)

15/11/2023

ID4031: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer

30/10/2025

ID6378: Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721)

31/10/2025

TA1102: Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)

31/10/2025

ID5082: Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments

14/11/2025

ID6415: Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

14/11/2025

ID6470: Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy